KalVista Pharmaceuticals, Inc.
(NASDAQ: KALV)

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

16.400

+1.740 (+11.87%)
Range 14.300 - 16.800   (17.48%)
Open 14.590
Previous Close 14.660
Bid Price 10.090
Bid Volume 11
Ask Price 10.630
Ask Volume 10
Volume 2,793,996
Value -
Remark
Delayed prices. Updated at 05 Dec 2025 05:00.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis